neuroprotection and clinical applications

clinical neuroprotection, not speculation

Semax's regulatory approval in Russia is based primarily on its neuroprotective effects in ischemic stroke. clinical studies have shown improvements in neurological outcomes when Semax is administered during the acute and recovery phases of ischemic brain injury. it is also approved for optic nerve atrophy and chronic cerebrovascular insufficiency.